Evidence map›Paper›PMID 38370479›Full record

ArticleFrontiers in pharmacology2024

Neurodegeneration: can metabolites from

Valeria Cavalloro, Nicoletta Marchesi, Pasquale Linciano, Daniela Rossi, Lucrezia Irene Maria Campagnoli, Alice Fossati, Karzan Mahmood Ahmed, Alessio Malacrida, Mariarosaria Miloso, Giuseppe Mazzeo and 8 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Foods (Basel, Switzerland) · 2026
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 5 institutions in 2 countries.

Valeria CavalloroDepartment of Earth and Environmental Sciences, University of Pavia, Pavia, Italy.
Nicoletta MarchesiDepartment of Drug Sciences, University of Pavia, Pavia, Italy.
Pasquale LincianoDepartment of Drug Sciences, University of Pavia, Pavia, Italy.
Daniela RossiDepartment of Drug Sciences, University of Pavia, Pavia, Italy.
Lucrezia Irene Maria CampagnoliDepartment of Drug Sciences, University of Pavia, Pavia, Italy.
Alice FossatiDepartment of Earth and Environmental Sciences, University of Pavia, Pavia, Italy.
Karzan Mahmood AhmedDepartment of Chemistry, College of Education, University of Garmian, Kalar, Iraq.
Alessio MalacridaSchool of Medicine and Surgery, University of Milan-Bicocca, Monza, Italy.
Mariarosaria MilosoSchool of Medicine and Surgery, University of Milan-Bicocca, Monza, Italy.
Giuseppe MazzeoDepartment of Molecular and Translational Medicine, Università di Brescia, Brescia, Italy.
Sergio AbbateDepartment of Molecular and Translational Medicine, Università di Brescia, Brescia, Italy.
Giovanna LonghiDepartment of Molecular and Translational Medicine, Università di Brescia, Brescia, Italy.
Francesca Alessandra AmbrosioDepartment of Experimental and Clinical Medicine, University "Magna Græcia" of Catanzaro, Campus "S. Venuta", Catanzaro, Italy.
Giosuè CostaDepartment of Health Sciences, Campus "S. Venuta", "Magna Græcia" University of Catanzaro, Catanzaro, Italy.
Stefano AlcaroDepartment of Health Sciences, Campus "S. Venuta", "Magna Græcia" University of Catanzaro, Catanzaro, Italy.
Alessia PascaleDepartment of Drug Sciences, University of Pavia, Pavia, Italy.
Emanuela MartinoDepartment of Earth and Environmental Sciences, University of Pavia, Pavia, Italy.
Simona CollinaDepartment of Drug Sciences, University of Pavia, Pavia, Italy.
University of Pavia · ITMagna Graecia University · ITUniversity of Brescia · ITUniversity of Milano-Bicocca · ITUniversity of Garmian

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The number of patients affected by neurodegenerative diseases is increasing worldwide, and no effective treatments have been developed yet. Although precision medicine could represent a powerful tool, it remains a challenge due to the high variability among patients. To identify molecules acting with innovative mechanisms of action, we performed a computational investigation using SAFAN technology, focusing specifically on HuD. This target belongs to the human embryonic lethal abnormal visual-like (ELAV) proteins and plays a key role in neuronal plasticity and differentiation. The results highlighted that the molecule able to bind the selected target was (

Indexed as

embryonic lethal abnormal visual-likeEremurus persicusHuDmolecular modelingnature-aided drug discoveryproteasome activators(R)-aloesaponol-III-8-methyl ether(R)-germichrysone

Identifiers

PMID38370479
PMCPMC10873958
OpenAlexW4391499905

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.